Table 2 Anti tumor effect

CR

PR

NC

PD

Response Rate (%)95%C.I. CR+PR/TOTAL

Clinical Response (%)95%C.I. CR+PR+NC/TOTAL

Over all

0

18

13

11

42.9 (27.7–59.0)

73.8 (58.0–86.2)

BDca

0

11

10

6

40.7 (22.4–61.2)

77.8 (57.8–91.4)

GBca

0

7

3

5

46.7 (21.1–73.5)

66.7 (38.4–88.2)

Primary or local recurrence

CR

PR

NC

PD

Response Rate (%)95%C.I. CR+PR/TOTAL

Clinical Response (%)95%C.I. CR+PR+NC/TOTAL

Over all

0

14

8

6

50.0 (30.6–69.4)

78.6 (59.0–91.7)

BDca

0

9

6

3

50.0 (26.0–74.0)

83.3 (58.6–96.5)

GBca

0

5

2

3

50.0 (18.6–81.4)

70.0 (34.7–93.5)

Metastatic lesion

CR

PR

NC

PD

Response Rate (%)95%C.I. CR+PR/TOTAL

Clinical Response (%)95%C.I. CR+PR+NC/TOTAL

Over all

0

10

12

9

32.3 (16.7–51.4)

71.0 (52.0–85.8)

BDca

0

6

9

5

30.0 (11.8–54.3)

75.0 (50.9–91.4)

GBca

0

4

3

4

36.4 (10.8–69.3)

66.7 (30.7–89.2)